Home Tags Synaffix

Tag: Synaffix

Synaffix Expands Licensing Agreement with Mersana

The Netherlands-based Synaffix, a biotechnology company focusing on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), confirmed the expansions of...

The 7th Annual World ADC Awards Winners – What’s Next

The World ADC Awards showcase companies, teams, and individuals in the industry, across 9 categories, at the forefront of cancer research today. Finalists and...

In vivo data Shows Efficacy of Synaffix’ Proprietary Exatecan Linker-Payload to...

In a poster presented during the virtual World ADC meeting, being held September 15 - 17, 2020 scientists at Synaffix showed early in vivo...

Synaffix and ADC Therapeutics Expand Collaboration

The Netherlands-based biotechnology company Synaffix and Swiss-based ADC Therapeutics have expanded the existing collaboration between the companies to explore additional applications of Synaffix’ site-specific...
Featured Image - Laboratory. Courtesy 2019 Fotolia

Shanghai Miracogen and Synaffix Confirm Expansion of License Agreement

Netherlands-based biotech company Synaffix earlier today confirmed the expansion of a license agreement with Shanghai Miracogen, a Chinese biotechnology company with a clinical-stage pipeline...

Abzena Confirms Successful Technical Transfer of Synaffix’s GlycoConnect™ and HydraSpace™ Technologies

Earlier today Abzena confirmed that it had successfully completed a technology transfer and scalability evaluation using the Synaffix's technologies of GlycoConnect™, site-specific antibody-drug conjugation...
Scientist pipetting

ADC Therapeutics Expands Agreement with Synaffix

The Netherlands-based biotechnology company Synaffix, which develops clinical-stage technologies for the development of best-in-class antibody-drug conjugates or ADCs, confirmed that ADC Therapeutics has triggered...

Dutch Biotech Signs License Agreement with Chinese ADC Developer

The Dutch biotech company Synaffix has signed a license agreement with the Chinese ADC developer Shanghai Miracogen. The agreement is estimated to be worth...

First Patient Dosed in Phase I Trial with Pyrrolobenzodiazepine-based Antibody-drug conjugate...

The development of proprietary, pyrrolobenzodiazepine-based, antibody-drug conjugates or ADCs targeting AXL, has entered a news phase with the dosing of the first patient in...

Mersana Therapeutics Focuses its Resources on Advancing XMT-1536, its First-in-Class ADC...

Mersana Therapeutics, a clinical-stage biopharmaceutical company developing a pipeline of antibody-drug conjugates or ADCs designed to target cancers in areas of high unmet need,...

X